ArrayPatch raises €3.2M seed for painless microneedle drug patches
What's the deal? Cork-based biotech ArrayPatchDealroom has a profile for this one. Try Dealroom → has completed an oversubscribed €3.2 million seed round, co-led by WakeUp CapitalDealroom has a profile for this one. Try Dealroom → and Lakeside CapitalDealroom has a profile for this one. Try Dealroom →. The financing closed in a second tranche that added €1.6 million to the total.
What's the endgame? ArrayPatch is building DerMap, a dissolving microneedle patch platform designed to deliver medicines through the skin without needles. Its lead program, GLP-DerMap, aims to deliver GLP-1 obesity and diabetes drugs via a pain-free patch.
The company says its microneedles are made entirely from the medicine being delivered, requiring no polymer and allowing higher drug loading. The platform can carry both small molecules and peptides.
What's the money for? The proceeds will accelerate progress toward first-in-human studies, with GLP-DerMap the priority. Other programs target basal cell carcinoma and onychomycosis, a nail fungal infection.
Who else is in? The round also drew Spark Venture Funding, Dr. Mark Ledwidge, DeepIE VenturesDealroom has a profile for this one. Try Dealroom →, Enterprise Ireland, and The Boole Investment SyndicateDealroom has a profile for this one. Try Dealroom →. WakeUp Capital partner Andrew Parish joins the board, alongside recently appointed chair Dr. Neil Thomas.
"The successful completion of our €3.2 million seed round is an important milestone for ArrayPatch and provides the resources to accelerate the development of our pipeline," said founder and chief executive officer Dr. Waleed Faisal.
By the numbers: The raise sits in the 93rd percentile among seed rounds in Irish health startups over the trailing 48 months, based on a sample of 62 deals. ArrayPatch was spun out from University College Cork.
The signal: Microneedle drug delivery is drawing investor attention, with US-based Anodyne Nanotech raising $12.6 million in a 2026 Series A to deliver GLP-1 and other biologics. For ArrayPatch, the test ahead is less about round size than whether its patches can prove clinical efficacy and a real delivery edge.
Read more: pr.lakeoconeebreeze.net
Image credit: Generated with Gemini
